RodriguesRF, RoqueL, KrugT, LeiteV. 2007. Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines. Br J Cancer, 96:1237–1245.
10.
Ricarte-FilhoJC, RyderM, ChitaleDA, RiveraM, HeguyA, LadanyiM, JanakiramanM, SolitD, KnaufJA, TuttleRM, GhosseinRA, FaginJA. 2009. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res, 69:4885–4893.
11.
ShawAT, MeissnerA, DowdleJA, CrowleyD, MagendantzM, OuyangC, ParisiT, RajagopalJ, BlankLJ, BronsonRT, StoneJR, TuvesonDA, JaenischR, JacksT. 2007. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev, 21:694–707.
12.
ChenX, MitsutakeN, LaPerleK, AkenoN, ZanzonicoP, LongoVA, MitsutakeS, KimuraET, GeigerH, SantosE, WendelHG, FrancoA, KnaufJA, FaginJA. 2009. Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci U S A, 106:7979–7984.
13.
CroyleM, AkenoN, KnaufJA, FabbroD, ChenX, BaumgartnerJE, LaneHA, FaginJA. 2008. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res, 68:4183–4191.
14.
NobuharaY, OnodaN, YamashitaY, YamasakiM, OgisawaK, TakashimaT, IshikawaT, HirakawaK. 2005. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer, 92:1110–1116.
15.
LandriscinaM, PiscazziA, FabianoA, MaddalenaF, CostantinoE, FareseA, BufoP, CignarelliM. 2009. Targeting epidermal growth factor receptor 1 signaling in human thyroid-stimulating hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype. Thyroid, 19:629–637.
16.
GuleM K, ChenY, SanoD, FrederickMJ, ZhouG, ZhaoM, MilasZL, GalerCE, HendersonYC, JasserSA, SchwartzDL, BanksonJA, MyersJN, LaiSY. 2011. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res, 17:2281–2291.
17.
YounesMN, YigitbasiOG, ParkYW, KimSJ, JasserSA, HawthorneVS, YaziciYD, MandalM, BekeleBN, BucanaCD, FidlerIJ, MyersJN. 2005. Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Cancer Res, 65:4716–4727.
18.
KnaufJA, SartorMA, MedvedovicM, LundsmithE, RyderM, SalzanoM, NikiforovYE, GiordanoTJ, GhosseinRA, FaginJA. 2011. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling. Oncogene, 30:3153–3162.
19.
Montero-CondeC, Martin-CamposJM, LermaE, GimenezG, Martinez-GuitarteJL, CombaliaN, MontanerD, Matias-GuiuX, DopazoJ, de LeivaA, RobledoM, MauricioD. 2008. Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information. Oncogene, 27:1554–1561.
20.
WisemanSM, MasoudiH, NiblockP, TurbinD, RajputA, HayJ, FilipenkoD, HuntsmanD, GilksB. 2006. Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. Am J Surg, 191:581–587.
21.
WisemanSM, GriffithOL, DeenS, RajputA, MasoudiH, GilksB, GoldsteinL, GownA, JonesSJ. 2007. Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma. Arch Surg, 142:717–727.
22.
VaskoV, EspinosaAV, ScoutenW, HeH, AuerH, LiyanarachchiS, LarinA, SavchenkoV, FrancisGL, de la ChapelleA, SajiM, RingelMD. 2007. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci U S A, 104:2803–2808.
23.
HardyKM, BoothBW, HendrixMJ, SalomonDS, StrizziL. 2010. ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia, 15:191–199.
24.
GrandeM, FranzenA, KarlssonJO, EricsonLE, HeldinNE, NilssonM. 2002. Transforming growth factor-beta and epidermal growth factor synergistically stimulate epithelial to mesenchymal transition (EMT) through a MEK-dependent mechanism in primary cultured pig thyrocytes. J Cell Sci, 115:4227–4236.
25.
SchweppeRE, KlopperJP, KorchC, PugazhenthiU, BenezraM, KnaufJA, FaginJA, MarlowL, CoplandJA, SmallridgeRC, HaugenBR. 2008. DNA Profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab, 15:1069–1074.
26.
LopezJP, Wang-RodriguezJ, ChangCY, SnehG, YuMA, PardoFS, AguileraJ, OngkekoWM. 2008. Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines. Laryngoscope, 118:1372–1376.
27.
PennellNA, DanielsGH, HaddadRI, RossDS, EvansT, WirthLJ, FidiasPH, TemelJS, GurubhagavatulaS, HeistRS, ClarkJR, LynchTJ. 2008. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid, 18:317–323.
28.
DiNF, MartiniM, MolinariF, Sartore-BianchiA, ArenaS, SalettiP, DeDS, MazzucchelliL, FrattiniM, SienaS, BardelliA. 2008. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 26:5705–5712.
29.
AmadoRG, WolfM, PeetersM, VanCE, SienaS, FreemanDJ, JuanT, SikorskiR, SuggsS, RadinskyR, PattersonSD, ChangDD. 2008. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol, 26:1626–1634.
30.
EberhardDA, JohnsonBE, AmlerLC, GoddardAD, HeldensSL, HerbstRS, InceWL, JannePA, JanuarioT, JohnsonDH, KleinP, MillerVA, OstlandMA, RamiesDA, SebisanovicD, StinsonJA, ZhangYR, SeshagiriS, HillanKJ. 2005. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 23:5900–5909.
31.
MassarelliE, Varella-GarciaM, TangX, XavierAC, OzburnNC, LiuDD, BekeleBN, HerbstRS, WistubaII. 2007. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res, 13:2890–2896.
32.
MasagoK, MiuraM, ToyamaY, TogashiY. Mishima M 2011 Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21. J Clin Oncol, 29:e465–e467.
33.
HoganT, JingJY, WilliamsHJ, AltahaR, XiaobingL, QiH. 2009. Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. J Oncol Pharm Pract, 15:111–117.
FujitaS, HigashiyamaT, MasagoK, MiyauchiA. Authors' reply to Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. Int J Cancer24Aug2011[Epub ahead of print]10.1002/ijc.26266.
36.
Ricarte-FilhoJC, MatsuseM, LauC, RyderM, NishiharaE, GhosseinRA, LadanyiM, YamashitaS, MitsutakeN, FaginJA. 2011. Absence of common activating mutations of the epidermal growth factor receptor gene in thyroid cancers from American and Japanese patients. Int J Cancer24Aug2011[Epub ahead of print]10.1002/ijc.26267.
37.
MuruganAK, DongJ, XieJ, XingM. 2011. Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers. Endocr Pathol, 22:97–102.
38.
MitsiadesCS, KotoulaV, PoulakiV, SozopoulosE, NegriJ, CharalambousE, FanourakisG, VoutsinasG, Tseleni-BalafoutaS, MitsiadesN. 2006. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab, 91:3662–3666.
39.
ShollLM, XiaoY, JoshiV, YeapBY, CioffrediLA, JackmanDM, LeeC, JannePA, LindemanNI. 2010. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol, 133:922–934.
